How Insulin Infusions Work with Normal Saline and Dextrose Solutions
Insulin infusions are prepared by diluting regular insulin in 0.9% normal saline at concentrations of 0.1-1.0 unit/mL for intravenous administration, with dextrose-containing fluids (typically 5-10% dextrose) added separately once blood glucose falls to prevent hypoglycemia while maintaining insulin's therapeutic effect. 1
Preparation and Administration
Standard Insulin Infusion Setup
For intravenous insulin infusions, regular insulin should be diluted in 0.9% sodium chloride (normal saline) at concentrations ranging from 0.1 to 1.0 unit/mL using polyvinyl chloride (PVC) infusion bags. 1 The FDA-approved formulation explicitly permits this preparation method for hospital use under medical supervision with close monitoring of blood glucose and potassium levels 1.
For critical care applications requiring higher concentrations, insulin can be safely prepared at 16 units/mL in normal saline and remains stable for 14 days both refrigerated and at room temperature, allowing treatment of severe overdoses without excessive fluid administration 2.
The Two-Solution System
The insulin infusion operates as a two-solution system:
- Primary insulin infusion: Regular insulin in normal saline runs continuously
- Dextrose solution: Added as a separate infusion when blood glucose decreases
This separation is critical—insulin and dextrose are NOT mixed together in the same bag for continuous infusions. The dextrose is administered through a separate line or added to maintenance fluids.
Clinical Application in DKA
Initial Phase (High Blood Glucose)
For diabetic ketoacidosis, start with 0.1 unit/kg/hour of regular insulin in normal saline (typically 5-7 units/hour in adults) after excluding hypokalemia (K+ >3.3 mEq/L) 3. This should decrease plasma glucose by 50-75 mg/dL per hour 3.
The insulin infusion runs alone initially—no dextrose is needed when blood glucose is elevated. The normal saline carrier solution provides the vehicle for insulin delivery while contributing to fluid resuscitation.
Transition Phase (Blood Glucose 250-300 mg/dL)
When plasma glucose reaches 250 mg/dL in DKA or 300 mg/dL in hyperosmolar hyperglycemic state (HHS), reduce the insulin infusion rate to 0.05-0.1 unit/kg/hour (3-6 units/hour) AND add dextrose (5-10%) to the intravenous fluids. 3
This critical transition prevents hypoglycemia while maintaining sufficient insulin to clear ketones and resolve metabolic acidosis. The dextrose is added to maintenance fluids or given as a separate infusion—NOT mixed directly with the insulin solution in the same bag.
Why This Two-Solution Approach Works
The separation allows independent titration:
- Insulin rate is adjusted based on ketone clearance and acid-base status
- Dextrose concentration/rate is adjusted based on blood glucose levels
Mixing insulin and dextrose in the same bag would create a fixed ratio that cannot be independently adjusted, leading to either persistent hyperglycemia (if you increase dextrose to match insulin) or hypoglycemia (if you maintain insulin delivery with insufficient dextrose).
Important Physicochemical Considerations
Insulin Stability and Absorption
Insulin exhibits significant adsorption to PVC tubing and containers, with up to 75% loss when concentrations are low (<400 ng/mL or roughly <7 units/L). 4, 5 However, at clinically relevant concentrations (≥25-50 units/L), this effect is minimized to acceptable levels 5.
Pre-treating the IV tubing by flushing with 100 mL of the insulin admixture or storing the solution in the tubing for 30 minutes reduces adsorption by 50-66%. 4 This is why many protocols recommend priming the line before starting the infusion.
Effect of Carrier Solution
Insulin bioavailability is significantly affected by the carrier solution. When insulin is added to total nutrient admixtures (containing amino acids), bioavailability reaches 28.8% of theoretical concentration compared to only 5.4% in plain saline 6. The amino acids appear to reduce insulin absorption to container walls 6.
For standard insulin infusions in critical care, normal saline remains the preferred carrier because:
- It's FDA-approved for this indication 1
- Stability data are well-established 1
- The lower bioavailability is predictable and accounted for in dosing protocols
Mixing Insulin with Other Insulins (Subcutaneous Use)
For subcutaneous administration, regular insulin CAN be mixed with NPH, lente, or ultralente insulins in the same syringe, but specific rules apply 7:
- Draw regular insulin (clear) FIRST, then intermediate-acting insulin (cloudy)
- Inject within 15 minutes of mixing when combining with intermediate/long-acting insulins
- Never mix insulin glargine with other insulins due to its low pH diluent 7
- Do NOT mix NPH with lente insulins—zinc phosphate precipitation occurs 7
These mixing guidelines apply to subcutaneous injections only—they are irrelevant for IV infusions where only regular insulin is used.
Critical Safety Points
Monitoring Requirements
Blood glucose must be monitored every 1-2 hours during insulin infusion to prevent hypoglycemia 8. Protocols checking glucose every 4 hours show hypoglycemia rates exceeding 10% 8.
Potassium levels require hourly monitoring or more frequently as needed during DKA treatment 3. Insulin drives potassium intracellularly, and hypokalemia is a major complication.
Hypoglycemia Prevention
When treating hypoglycemia in patients on insulin infusions, use titrated dextrose replacement: 10% dextrose in 5-gram aliquots (50 mL) repeated every minute until symptoms resolve. 8 This approach corrects blood glucose to target range in 98% of cases within 30 minutes while avoiding overcorrection 8.
The traditional 50% dextrose bolus (25 grams) causes excessive glucose elevation (median 169 mg/dL vs. 112 mg/dL with 10% dextrose) and should be avoided 8.
Common Pitfalls
Delaying dextrose addition when glucose reaches 250-300 mg/dL: This significantly increases hypoglycemia risk during both active DKA treatment and the entire hospitalization 9
Stopping basal insulin in type 1 diabetes patients: Even when on insulin infusion, patients with type 1 diabetes must continue basal insulin to prevent ketoacidosis if the infusion is interrupted 10
Using incorrect insulin type: Only regular (short-acting) insulin should be used for IV infusions—never rapid-acting analogs, which are not FDA-approved for IV use 1
Inadequate line priming: Failure to prime the IV tubing with insulin solution leads to unpredictable initial dosing due to adsorption 4
Special Populations
Pediatric DKA
In children, low-dose insulin (0.05 unit/kg/hour) shows comparable efficacy to standard dose (0.1 unit/kg/hour) with significantly fewer complications: hypoglycemia (3.3% vs. 13.3%) and hypokalemia (30% vs. 43.3%) 11.
Enteral/Parenteral Nutrition
For patients on continuous tube feeding requiring insulin, use NPH every 8-12 hours to cover nutritional needs (approximately 1 unit per 10-15 grams carbohydrate), plus correctional rapid-acting insulin every 4 hours. 10 If tube feeding is interrupted, immediately start 10% dextrose infusion at 50 mL/hour to prevent hypoglycemia 10.